What It Is This research peptide blend combines two advanced synthetic peptides: GLP3 (a 39-amino acid triple agonist) and Cagrilintide (a long-acting amylin analog)
J., Lee, H., Jeon, E., Chung, S., Hong, Y
The medications' effect on gastric emptying and reduced caloric intake creates a sustained energy deficit, which triggers metabolic adaptations aimed at conserving energy
This indicates that DSIP specifically improves ATP synthesis efficiency rather than simply increasing overall oxygen consumption or causing uncoupling [2]
After 68 weeks, half of the subjects using semaglutide lost 15% of their body weight, and almost a third lost 20%
For most people, including those with thyroid conditions (except MTC and MEN2), the benefits of treatment outweigh theoretical thyroid concerns that have not been confirmed in human studies